Activated Partial Thromboplastin Time and Outcome after Thrombolytic Therapy for Acute Myocardial Infarction Results from the GUSTO-I Trial

Circulation

Volumn 93, Issue 5, 1996, Pages 870-878

  Granger, Christopher B ^a   Hirsh, Jack ^b   Califf, Robert M ^a   Col, Jacques ^c   White, Harvey D ^d   Betriu, Amadeo ^e   Woodlief, Lynn H ^a   Lee, Kerry L ^a   Bovill, Edwin G ^f   Simes, R John ^g   Topol, Eric J ^h  

^a DUKE UNIVERSITY   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d GREEN LANE HOSPITAL   (New Zealand)

^e HOSPITAL CLÍNIC   (Spain)

^f UNIVERSITY OF VERMONT   (United States)

^g UNIVERSITY OF SYDNEY   (Australia)

^h LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anticoagulants; Heparin; Myocardial infarction; Thrombolysis; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ARTICLE; BLEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; FEMALE; FIBRINOLYTIC THERAPY; HEART REINFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; BODY WEIGHT; CEREBROVASCULAR DISORDERS; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PARTIAL THROMBOPLASTIN TIME; PROGNOSIS; RANDOM ALLOCATION; RECURRENCE; SEX FACTORS; SMOKING; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0029938993     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.5.870     Document Type: Article

References (36)

1. Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/ American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee to develop guidelines for the early management of patients with acute myocardial infarction). J Am Coll Cardiol. 1990;16:249-292.
2. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
3. Hsia J, Kleiman NS, Aguirre FV, Chaitman BR, Roberts R, Ross AM. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. J Am Coll Cardiol. 1992;20:31-35.
4. Arnout J, Simoons M, de Bono D, Rapold HJ, Collen D, Verstraete M. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol. 1992;20: 513-519.
5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;349-360.
6. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised trial of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770.
7. Gruppo Italiano per lo Studio della Stretochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-402.
8. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet. 1990;336:65-71.
9. The GUSTO-I Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
10. Granger CB, Califf RM, Hirsh J, Woodlief LH, Topol EJ. APTTs after thrombolysis and standard intravenous heparin are often low and correlate with body weight, age and sex: experience from the GUSTO-I trial. Circulation. 1992;86(suppl I):I-258. Abstract.
11. GUSTO Gazette. 1992;5/6:1.
12. Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med. 1991;151:333-337.
13. Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood. 1977;49:171-184.
14. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML, for the TIMI Investigators. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1-11.
15. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, Simoons M, Aylward P, van de Werf F, Califf RM, for the GUSTO-I Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41 021 patients. Circulation. 1995;91:1659-1668.
16. Devlin TF, Weeks BJ. Spline functions for logistic regression modeling. Proc 11th Annual SAS Users Group International Conference. Cary, NC: SAS Institute Inc; 1986:646-651.
17. Cipolle R, Seifert R, Neilan B, Zaske DE, Haus E. Heparin kinetics: variables related to disposition and dosage. Clin Pharmacol Ther. 1981;29:387-393.
18. Flaker G, Bartolozzi J, Davis V, McCabe C, Cannon C, for the TIMI 4 Investigators. Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction. Arch Intern Med. 1994;1492-1496.
19. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a 'standard care' nomogram: a randomized controlled trial. Ann Intern Med. 1993;119:874-881.
20. Estes JW. The fate of heparin in the body. Curr Ther Res. 1975;18: 45-57.
21. Glimelius B, Busch C, Hook M. Binding of heparin on the surface of cultured human endothelial cells. Thromb Res. 1978;12:773-782.
22. Friedman Y, Arsenis C. Studies on the heparin sulphamidase activity from rat spleen: intracellular distribution and characterization of the enzyme. Biochem J. 1974;139:699-708.
23. Perry PT, Herin GR, King JC. Heparin half-life in normal and impaired renal function. Clin Pharmacol Ther. 1974;16:514-519.
24. Mahaffey KW, Granger CB, O'Connor CM, Ohman EM, Bleich SD, Col J, Califf RM. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol. In press.
25. Levine MN, Hirsh J, Kelton JG. Heparin-induced bleeding. In: Lane DA, Lindahl U, eds. Heparin: Chemical and Biological Properties and Clinical Applications. London: Edward Arnold; 1989:517-532.
26. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis D, Lambrew CT, Leiboff R, Mann KG, Markis JE, Pratt CM, Sharkey SW, Sopko G, Tracy RP, Chesebro JIl, for the TIMI Investigators. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med. 1991;115:256-265.
27. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation. 1994;90:1624-1630.
28. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-1637.
29. Simoons ML, Maggioni AP, Knatterud G, Leimberger JD, de Jaegere P, van Domburg R, Boersma E, Franzosi MG, Califf R, Schroder R, Braunwald E. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet. 1993; 342:1523-1528.
30. SCATI Investigators. Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction: the SCATI (Studio sulla Calciparina nell'Angina e nella Trombosi Ventricolare nell'Infarto) Group. Lancet. 1989;2:182-186.
31. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 1992;327:141-145.
32. Chen J, Karlberg KE, Sylven C. Heparin enhances platelet aggregation irrespective of anticoagulation with citrate or with hirudin. Thromb Res. 1992;67:253-262.
33. Granger CB, Miller J, Bovill EG, Gruber A, Tracy RP, Krucoff MW, Green C, Berrios E, Harrington RA, Ohman EM, Califf RM. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation. 1995;91:1929-1935.
34. Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet. 1977;2:581-584.
35. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med. 1993;119: 104-109.
36. D'Angelo A, Seveso MP, D'Angelo SV, Gilardoni F, Dettori AG, Bonini P. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT): implications in heparin monitoring by APTT. Am J Clin Pathol. 1990;94:297-306.